A Randomized Phase II Study Investigating the Addition of the Specific COX-2 Inhibitor Celecoxib to Docetaxel Plus Carboplatin As First-Line Chemotherapy for Stage IC to IV Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinomas: the DoCaCel Study.
Annals of Oncology（2012）
Key words
carboplatin,celecoxib,docetaxel,epithelial ovarian cancer,first-line chemotherapy,randomized phase II study
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined